Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.44 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27157713 | 0.95 | TYMP (0.48) | TYMPNT5MTK1RNASE1TK2 | |
| SCHEMBL29129493 | 0.89 | NT5M (0.42) | NT5MTK1LMNATSHRALB | |
| SCHEMBL19660825 | 0.85 | TK1 (0.45) | TK1RNASE1TK2 | |
| SCHEMBL27157933 | 0.84 | TK1 (0.41) | TYMPNT5MTK1RNASE1 | |
| SCHEMBL441127 | 0.84 | RNASE1 (0.50) | TK1LMNATSHRALBPKM | |
| SCHEMBL409820 | 0.84 | RNASE1 (0.50) | TK1LMNATSHRALBPKM | |
| SCHEMBL29975987 | 0.83 | NT5M (0.38) | TYMPNT5MTK1RNASE1TK2 | |
| SCHEMBL19953995 | 0.82 | TK1 (0.44) | TK1RNASE1TK2 | |
| SCHEMBL30177217 | 0.82 | NT5M (0.41) | NT5MTK1LMNAALBPKM | |
| SCHEMBL23713976 | 0.80 | TK1 (0.44) | NT5MTK1RNASE1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2024-08-01 | — | — | US | disclosed |
| EP-4332111-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022230954-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, CYC1, MRM1 | TYMP 319/4885NT5M 2378/4885TK1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.